Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 96.11B +31.9% |
| Revenue (ttm) | 16.90B +18.6% |
| Net Income | 4.82B +5.2% |
| EPS | 45.17 +8.6% |
| Shares Out | 100.35M |
| PE Ratio | 21.21 |
| Forward PE | 11.85 |
| Dividend | $3.76 (0.39%) |
| Ex-Dividend Date | Nov 20, 2026 |
| Volume | 933,408 |
| Open | 952.56 |
| Previous Close | 952.40 |
| Day's Range | 946.94 - 965.48 |
| 52-Week Range | 591.52 - 991.73 |
| Beta | 0.10 |
| Analysts | Buy |
| Price Target | 990.81 (+3.45%) |
| Earnings Date | Oct 30, 2026 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for REGN stock is "Buy." The 12-month stock price target is $990.81, which is an increase of 3.45% from the latest price.
News
CytomX Therapeutics triggers $5M milestone payment in Regeneron collaboration
CytomX Therapeutics (CTMX) announced the achievement of a preclinical milestone for one of the lead programs in its collaboration with Regeneron (REGN), triggering a $5M milestone payment. The Regener...
Regeneron Pharmaceuticals Transcript: Jefferies Global Healthcare Conference
Q3 revenue and non-GAAP EPS rose 36% and ~70% YoY, led by EYLEA HD, LIBTAYO, and DUPIXENT. Priorities include advancing pipeline programs, investing in R&D, and pursuing disciplined BD; EYLEA HD’s prefilled syringe decision is targeted by year-end 2026.
Regeneron reports EC approval for Libtayo alternative, flexible dosing schedule
Regeneron (REGN) announced that the European Commission, or EC, has approved an alternative, flexible dosing schedule for Libtayo across all approved skin, lung and cervical cancer indications. The EC...
Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications
Approval introduces an extended dosing regimen of Libtayo 700 mg given every six weeks, following initial 12 weeks of treatment with Libtayo 350 mg every three weeks Also approved is an option of redu...
Regeneron price target raised to $1,075 from $917 at Barclays
Barclays raised the firm’s price target on Regeneron (REGN) to $1,075 from $917 and keeps an Overweight rating on the shares.
REGN Price Forecast: Rally Faces Resistance After 37% Advance
Regeneron shares face growing resistance after a 37% advance, with potential correction targets emerging while the intermediate- and long-term bullish trends remain intact.
Regeneron’s baloncibart reduces orthostatic heart rate in Phase 2 trial
Regeneron (REGN) announced results from the Phase 2 PINNACLE trial in adults with postural orthostatic tachycardia syndrome, or POTS, evaluating baloncibart, a novel, investigational, first-in-class m...
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
Data presented today for the first time at the American Autonomic Society (AAS) annual meeting POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked in...
Alnylam says Regeneron advances CIDEBsiRNA with FIH results in MASLD patients
Alnylam Pharmaceuticals (ALNY) announced that its collaborator, Regeneron Pharmaceuticals (REGN), shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CID...
Regeneron Pharmaceuticals Transcript: Investor update
The Genetics Center has enabled nearly 50 target discoveries or validations, with six programs in the clinic. CIDEB siRNA cut liver fat by up to 80% in early data and is advancing into registrational-intent studies, amid a projected $15B-plus U.S. MASH market by 2035.
Regeneron Pharmaceuticals Slides: Investor update
Regeneron Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2026.
Regeneron announces results from trial of CIDEBsiRNA
Regeneron (REGN) Pharmaceuticals announced the first results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA rapidly normalized liver fat and improved liver inju...
CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD
Single administration of CIDEB siRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Jefferies Global Healthcare Conference in Londo...
Regeneron price target raised to $913 from $810 at RBC Capital
RBC Capital raised the firm’s price target on Regeneron (REGN) to $913 from $810 and keeps a Sector Perform rating on the shares. The company’s strong commercial quarter underscores the…
Regeneron price target raised to $997 from $835 at Leerink
Leerink analyst David Risinger raised the firm’s price target on Regeneron (REGN) to $997 from $835 and keeps a Market Perform rating on the shares following significant Q3 results upside.
Regeneron price target raised to $982 from $780 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Regeneron (REGN) to $982 from $780 and keeps a Buy rating on the shares. The company posted strong top- and…
Regeneron price target raised to $980 from $795 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Regeneron (REGN) to $980 from $795 and keeps an Overweight rating on the shares. The firm sees “something closer to ~$80/share” in…
Regeneron price target raised to $1,100 from $1,030 at Guggenheim
Guggenheim raised the firm’s price target on Regeneron (REGN) to $1,100 from $1,030 and keeps a Buy rating on the shares.
Regeneron price target raised to $1,175 from $922 at Canaccord
Canaccord raised the firm’s price target on Regeneron (REGN) to $1,175 from $922 and keeps a Buy rating on the shares. The firm said Dupixent’s impressive beat vs consensus reaffirms…
Regeneron price target raised to $875 from $761 at Baird
Baird analyst Brian Skorney raised the firm’s price target on Regeneron (REGN) to $875 from $761 and keeps a Neutral rating on the shares. The firm updated its model following…
Regeneron price target raised to $812 from $756 at Bernstein
Bernstein raised the firm’s price target on Regeneron (REGN) to $812 from $756 and keeps a Market Perform rating on the shares. The firm notes Regeneron delivered a strong Q3…
Regeneron price target raised to $925 from $750 at Wells Fargo
Wells Fargo raised the firm’s price target on Regeneron (REGN) to $925 from $750 and keeps an Equal Weight rating on the shares. The firm cites the company’s strong commercial…
Regeneron price target raised to $1,030 from $908 at BofA
BofA raised the firm’s price target on Regeneron (REGN) to $1,030 from $908 and keeps a Buy rating on the shares. The company reported solid Q3 results across key products,…
Regeneron price target raised to $855 from $779 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron (REGN) to $855 from $779 and keeps an Equal Weight rating on the shares. The firm views the…